Drugs / CD70-targeted CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07181720 | Sep 2025 → Mar 2028 expected | cervical cancer, lung cancer, ovarian cancer, renal cell carcinoma +2 | Chongqing Precision Biotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD70-targeted CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07181720 ↗ |
| Modality | Cell therapy | “CD70-targeted CAR-T cell preparations” NCT07181720 ↗ |
| Target | CD70 | “CD70-targeted CAR-T cells” NCT07181720 ↗ |